[go: up one dir, main page]

WO2006128176A3 - Composite molecules comprising g-csf function - Google Patents

Composite molecules comprising g-csf function Download PDF

Info

Publication number
WO2006128176A3
WO2006128176A3 PCT/US2006/020917 US2006020917W WO2006128176A3 WO 2006128176 A3 WO2006128176 A3 WO 2006128176A3 US 2006020917 W US2006020917 W US 2006020917W WO 2006128176 A3 WO2006128176 A3 WO 2006128176A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
csf
composite molecules
csf function
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020917
Other languages
French (fr)
Other versions
WO2006128176A2 (en
Inventor
Darryl L Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nora LLC
Original Assignee
Nora LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nora LLC filed Critical Nora LLC
Publication of WO2006128176A2 publication Critical patent/WO2006128176A2/en
Publication of WO2006128176A3 publication Critical patent/WO2006128176A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to granulocyte colony-stimulating factor ('G-CSF') composite fusion molecules and compositions containing such molecules which retain the functions of G-CSF, relating to, for example, reproductive fitness. Also provided are methods for determining and preparing analogs, derivatives, hybrid molecules and modifications.
PCT/US2006/020917 2005-05-26 2006-05-26 Composite molecules comprising g-csf function Ceased WO2006128176A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68472405P 2005-05-26 2005-05-26
US60/684,724 2005-05-26

Publications (2)

Publication Number Publication Date
WO2006128176A2 WO2006128176A2 (en) 2006-11-30
WO2006128176A3 true WO2006128176A3 (en) 2007-01-11

Family

ID=37452997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020917 Ceased WO2006128176A2 (en) 2005-05-26 2006-05-26 Composite molecules comprising g-csf function

Country Status (1)

Country Link
WO (1) WO2006128176A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP2198875A1 (en) 2003-10-24 2010-06-23 Nora, LLC A method for reducing the likelihood of preterm labour in a subject in need thereof
WO2010126528A1 (en) * 2009-05-01 2010-11-04 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
WO2021123033A1 (en) 2019-12-17 2021-06-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel g-csf mimics and their applications

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABE ET AL.: "A Patient with Cyclic Neutropenia Complicated by Severe Persistent Neutropenia Successfully Delivered a Healthy Baby", INTERNAL MEDICINE, vol. 39, no. 8, August 2000 (2000-08-01), pages 663 - 666, XP008075549 *
COX ET AL.: "Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein", EXPERIMENTAL HEMATOLOGY, vol. 32, 2004, pages 441 - 449, XP003006681 *

Also Published As

Publication number Publication date
WO2006128176A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2007076032A3 (en) Compositions and methods for producing a composition
WO2006028936A3 (en) Heteromultimeric molecules
WO2008027812A3 (en) Imidazopyridine and imidazopyrimidine derivatives
WO2004035170A3 (en) Composition for separating molecules
MX2007013632A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein.
WO2006020276A3 (en) Antiviral compounds
WO2006072393A3 (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
WO2007062399A3 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
EG25613A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
WO2007112028A3 (en) 2'-fluoronucleoside phosphonates as antiviral agents
WO2003093269A3 (en) Substituted pyrazolo-pyrimidine-4-ones
WO2008048589A3 (en) Compounds and methods for treatment of hcv
WO2009023844A3 (en) 3' substituted compounds having 5-ht6 receptor affinity
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
WO2003006070A3 (en) Improved chelator conjugates
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
WO2006091457A3 (en) Ionic liquids derived from peracid anions
ZA200604410B (en) Imidazole derivatives, processes for preparing them and their uses
WO2006119400A3 (en) Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-trianzin-6-ones, and their use as fungicides
WO2006114520A3 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
WO2007083060A3 (en) Novel chalcone derivatives with antimitotic activity
WO2004106322A3 (en) Polymorphs of aripiprazole
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
WO2006128176A3 (en) Composite molecules comprising g-csf function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06771595

Country of ref document: EP

Kind code of ref document: A2